how big is Accretion Pha.?

No Data Available for the Stock

What does Accretion Pha. do?

No Company Information Available

When is the next results date for Accretion Pha.?

No Upcoming Board Meetings

Has Accretion Pha. declared dividend?

No Dividend History Available

Who are the peers of the Accretion Pha.?

No Peers Information Available

How has been the historical performance of Accretion Pha.?

Accretion Pha. has shown significant growth from March 2024 to March 2025, with net sales increasing from 13.35 Cr to 57.38 Cr, and profit after tax rising from 1.49 Cr to 6.79 Cr. Key metrics such as operating profit and earnings per share also improved markedly, indicating strong overall financial performance.

Answer:<BR>The historical performance of Accretion Pha. shows significant growth over the past three years, particularly from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Accretion Pha. experienced a substantial increase in net sales, rising from 13.35 Cr in March 2024 to 57.38 Cr in March 2025. This growth in total operating income was accompanied by a rise in raw material costs, which increased from 15.17 Cr to 43.71 Cr during the same period. The total expenditure also rose significantly, from 10.79 Cr to 45.50 Cr. However, the operating profit (PBDIT) improved markedly, reaching 11.97 Cr in March 2025, up from 2.61 Cr in March 2024. Profit before tax also saw a notable increase, climbing to 9.76 Cr from 2.00 Cr. Consequently, profit after tax surged to 6.79 Cr in March 2025, compared to 1.49 Cr in March 2024. The earnings per share (EPS) reflected this growth, increasing from 3.73 to 8.31. On the balance sheet, total assets grew from 27.44 Cr to 39.87 Cr, while total liabilities increased from 27.44 Cr to 39.87 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved from -11.00 Cr to 5.00 Cr, showcasing a positive shift in cash generation. Overall, Accretion Pha. demonstrated a strong upward trend in financial performance across key metrics.

Is Accretion Pha. overvalued or undervalued?

As of November 27, 2025, Accretion Pharmaceuticals is considered overvalued with a PE ratio of 15.23 and an EV to EBITDA of 9.35, despite a recent 63.82% stock return, as it is still more attractively priced than peers like Sun Pharma and Divi's Lab, which have much higher PE ratios.

As of 27 November 2025, the valuation grade for Accretion Pharmaceuticals has moved from fair to expensive, indicating a shift in perception regarding its market value. The company is currently assessed as overvalued. Key ratios include a PE ratio of 15.23, an EV to EBITDA of 9.35, and a ROCE of 20.47%. <BR><BR>In comparison to its peers, Accretion's PE ratio is significantly lower than Sun Pharma's 37.62 and Divi's Lab's 69.34, both categorized as very expensive. This suggests that while Accretion may appear expensive relative to its own historical valuation, it is still more attractively priced compared to some of its higher-valued competitors. Despite recent stock performance showing a 63.82% return over the past month compared to a mere 0.96% for the Sensex, the overall valuation metrics indicate that Accretion Pharmaceuticals is not justified at its current price level.

Which are the latest news on Accretion Pha.?

Why is Accretion Pha. falling/rising?

As of 04-Dec, Accretion Pharmaceuticals Ltd's stock price is rising to 88.05, up 4.88%, driven by a 55.15% increase over the past month, outperforming the Sensex. Despite a drop in investor participation, the stock remains above key moving averages, indicating a positive trend.

As of 04-Dec, Accretion Pharmaceuticals Ltd's stock price is rising, currently at 88.05, reflecting an increase of 4.1 or 4.88%. This upward movement can be attributed to its strong performance over the past month, where the stock has surged by 55.15%, significantly outperforming the Sensex, which only increased by 1.70% during the same period. <BR><BR>Additionally, today's performance indicates that the stock has outperformed its sector by 4.59%. Despite a decline in investor participation, as evidenced by a 53.7% drop in delivery volume compared to the 5-day average, the stock remains above its 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally positive trend in its price movement. <BR><BR>Overall, the combination of substantial recent gains and current price performance relative to benchmarks supports the conclusion that Accretion Pharmaceuticals Ltd's stock is experiencing a rise.